登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2026-8 广西梧州中恒集团股份有限公司 关于控股孙公司纳米炭铁混悬注射液联合放疗II期 临床试验获得伦理批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控股子公司重庆莱美药业股份 有限公司（以下简称"莱美药业"）之子公司四川瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研 发的"纳米炭铁混悬注射液"（以下简称"纳米炭铁"）于近期在四川大学华西医院顺利通过了伦理审查并 收到了临床试验伦理审查委员会的正式批件，标志着纳米炭铁联合放疗正式进入II期临床试验阶段。现 将相关情况公告如下： 一、纳米炭铁临床试验进展情况 目前，纳米炭铁的I期临床试验已顺利完成，主要评估不同剂量的纳米炭铁单药单次给药在晚期实体瘤 患者中的安全性、耐受性、药代动力学特征和初步疗效。纳米炭铁IbIIa期临床试验已完成部分受试者入 组，疗效随访中，主要评估不同剂量的纳米炭铁 ...

Core Viewpoint - In 2025, Laimei Pharmaceutical achieved significant milestones in innovation and product development, enhancing its position in the pharmaceutical industry through successful clinical trials and recognition for its innovative products. Group 1: Innovation and R&D - The clinical trial for the innovative anti-cancer drug "Nano Carbon Iron Suspension Injection" was approved, allowing it to be tested in solid tumor patients [2][4] - The drug is based on the existing Nano Carbon Suspension Injection and utilizes Fe2+ as an active anti-cancer component [4] - Laimei's generic drug "Mabalaoshuwei Tablets" received ethical approval and entered the bioequivalence trial phase [5] - "Nano Carbon Suspension Injection" was selected as one of the first batch of iconic products in future industries by the Chongqing Municipal Economic and Information Technology Commission [8] - "Injection Esomeprazole Sodium" was recognized as a major industrial technology innovation product for 2024 by the Chongqing Municipal Economic and Information Technology Commission [10] Group 2: Market Expansion and Product Selection - Laimei's product "Nicorandil Tablets" was selected in the 11th batch of national drug centralized procurement, marking its entry into the mainstream medical market [12][13] - Multiple products from Laimei were selected in the Guangdong Alliance centralized procurement, enhancing accessibility to essential medications [15][16][18] Group 3: Brand Recognition and Awards - Laimei was included in the "Top 50 Comprehensive Strength List" of the 2024 China Innovative Drug Value Ranking, reflecting its commitment to innovation [22] - The company received the "Golden Information Disclosure Award" for the second consecutive year, recognizing its excellence in information disclosure and compliance [24] - Laimei was awarded the title of "Leading Enterprise in Manufacturing Innovation" by the Chongqing Economic Development Zone [26] - The company was recognized as a "Pilot Enterprise for Strong Party Building" in the Nanan District, highlighting its commitment to governance and community engagement [31]

Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Sichuan Yingrui Pharmaceutical Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, Nano Carbon Iron Suspension Injection, in combination with standard radiotherapy for solid tumor patients [1][2]. Group 1: Drug Information - The drug, named Nano Carbon Iron Suspension Injection, is developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd. and is classified as a Class 2 chemical drug [1]. - The drug targets solid tumors and utilizes Fe2+ as the active anti-cancer component, with nano carbon serving as its carrier, aiming to regulate ferroptosis pathways for anti-cancer effects [2]. - The clinical trial will explore the safety and potential efficacy of the combination therapy of Nano Carbon Iron and radiotherapy, particularly in challenging solid tumors [2]. Group 2: Research and Development - The cumulative R&D expenses for Nano Carbon Iron have reached approximately 94.28 million RMB (around 14.5 million USD) as of the announcement date [3]. - The second phase of clinical trials for Nano Carbon Iron is progressing smoothly, with some patient enrollment already completed [2]. - There are currently no similar products on the market or in late-stage research that directly target the ferroptosis pathway with exogenous Fe2+ [2].

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [1][2] Group 1: Product Development - The drug "Nano Carbon Iron" is a next-generation nano drug developed based on Laimei's existing product, utilizing Fe2+ as the active anti-cancer ingredient and nano carbon as its carrier [1] - The mechanism of action involves regulating ferroptosis pathways to exert anti-cancer effects, with the drug administered via intratumoral injection to inhibit tumor growth [1] Group 2: Clinical Trial and Mechanism - The approved clinical trial will explore the safety and potential efficacy of the combination of "Nano Carbon Iron" and standard radiotherapy in treating solid tumors [2] - Research indicates that the mechanisms of action of "Nano Carbon Iron" and radiotherapy are complementary, potentially enhancing the local treatment effects, especially in large, hypoxic tumors that are difficult to control with radiotherapy alone [2]

Core Viewpoint - Lai Mei Pharmaceutical's subsidiary Yingrui Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [2] Group 1: Product Development - The new generation nano drug, Nano Carbon Iron, is developed based on the existing Nano Carbon Suspension Injection, utilizing Fe2+ as the active anti-cancer ingredient [2] - Nano Carbon serves as a carrier for Fe2+, and the drug exerts its anti-cancer effects by regulating the ferroptosis pathway [2] Group 2: Clinical Trials - The second phase of clinical trials for Nano Carbon Iron is progressing smoothly, with some patient enrollments already completed [2] - There are currently no similar products on the market or in late-stage research [2]